~HemoShear to deliver four presentations at the world’s leading conference on liver diseases and treatment approaches~
~Arun Sanyal, M.D., to give oral presentation on the pharmacology and toxicology of obeticholic acid~
[Charlottesville, VA – November 12, 2015] -- HemoShear Therapeutics, LLC, a biotechnology company focused on discovering drugs for metabolic disorders, today announced that it will present data from four separate programs that demonstrate the diverse drug discovery and safety applications of its REVEAL-TxTM platform at the 2015 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), from November 13-17, 2015, at the Moscone West Convention Center in San Francisco, California.
“The study data we are presenting at AASLD illustrate our platform’s ability to identify mechanisms of drug efficacy and toxicity that are currently not possible in other in vitro models,” said Brian Wamhoff, Ph.D., Head of R&D. “We are particularly excited about the data that Dr. Sanyal will be discussing at his oral presentation on the efficacy and safety of the non-alcoholic steatohepatitis (NASH) drug, obeticholic acid, which were acquired using HemoShear’s proprietary human liver tissue models, exposed to clinically relevant concentrations of the drug.”
NASH is a common, often silent, liver disease with histological features of fatty liver, inflammation and fibrosis, which may progress to cirrhosis.
These research studies were funded in part by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases.
The accepted abstracts are listed below and are now available online on the AASLD conference website: http://www.aasld.org/events-professional-development/liver-meeting/program-0/2015-abstracts-full-text.
Presentation Title: Transcriptomic Analysis Of Human Hepatocytes In 3-Dimensional Cultures With Maintained Perfusion And Transport Offers Insights Into The Pharmacotoxicology Of Clinically Relevant Concentrations Of Obeticholic Acid.
Session Date and Time: November 16, 2015 from 4:45 PM to 6:15 PM
Abstract Number: 175
Presentation Time: 4:45 PM to 5:00 PM
Session: Parallel 26: Hepatotoxicity: Pathogenesis and Mechanisms
Room: 3020 (Moscone Center)
Summary: An oral presentation by Dr. Arun Sanyal, Charles Caravati Professor and chair, Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University, discusses mechanistic insights into the efficacy and safety of the nonalcoholic steatohepatitis (NASH) drug, obeticholic acid, acquired using HemoShear’s healthy and disease liver tissue models.
Presentation Title: Assessment of Donor and Environmental Risk Factors in a Human Physiologically Relevant Model of Nonalcoholic Steatohepatitis (NASH).
Session Title: Experimental Steatohepatitis
Date & Time: November 15, 2015 (12:30pm – 2:00pm)
Abstract Number: 915
Summary: HemoShear Therapeutics describes the development of its proprietary, physiologically relevant model of nonalcoholic steatohepatitis (NASH).
Presentation Title: Restoration of Hepatic Physiological Parameters in vitro Influences Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) and LDL Regulation by Atorvastatin.
Session Title: Signal Transduction, Nuclear Receptors
Date & Time: November 14, 2015 (5:30pm – 7:00pm)
Abstract Number: 664
Summary: HemoShear Therapeutics describes the regulation of lipoprotein biology and PCSK9 secretion in the HemoShear liver model in response to the cholesterol-lowering drug Atorvastatin.
Presentation Title: Transcriptional Profiling On Primary Hepatocytes Under Hemodynamics And Transport Differentiates Distinct Mechanisms Of Drug-Induced Liver Injury.
Session Title: Drug Metabolism and Toxicity
Date & Time: November 17, 2015 (10:30am – 12:00pm)
Abstract Number: 1916
Summary: HemoShear Therapeutics presents toxicology data that profiles unique and distinct drug-induced liver injury (DILI) signatures of four different hepatotoxic drugs.
About HemoShear Therapeutics
HemoShear Therapeutics is a biotechnology company focused on discovering drugs that treat metabolic disorders. Our transformational tissue models allow us to understand human diseases at a level not possible until now. Our current drug discovery programs are focused on organic acidemias, a group of rare genetic metabolic disorders, and nonalcoholic steatohepatitis (NASH).
At HemoShear Therapeutics, we believe that precision matters: best in class models of human disease lead to meaningful drug targets and optimal therapies. We THINK HUMAN.
REVEAL-Tx™, HemoShear Therapeutics proprietary discovery platform is agnostic to therapeutic modality and provides a powerful lens to interrogate biological mechanisms of human disease to identify novel targets and biomarkers and to create superior therapeutics.
Feinstein Kean Healthcare
M 508 851 0930